NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT04676360 2026-03-13
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT05064358 2025-10-07
DREAMM 14
GlaxoSmithKline
Phase 2 Active not recruiting
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT06956170 2025-06-11
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868667 2025-05-09
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT06868654 2025-04-23
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting